Meetings between the Food and Drug Administration (FDA) and industry sponsors are critical to conducting effective and efficient drug development and bringing life-changing, innovative medicines to patients. The purpose of this White Paper is to highlight the importance of timely, substantive, and collaborative communication through well-constructed interactions between sponsors and FDA during drug development and the review process. It highlights best practices for sponsors and FDA for meeting-based interactions that ultimately lead to enhanced public health.
